Abstract
Background
Mitochondrial tumor suppressor gene 1 (MTUS1) has been recently identified as a candidate tumor suppressor gene which resides in a genomic region (8p22) that shows frequent loss of heterozygosity (LOH) in several tumor types. It has been suggested that multiple gene promoters and alternative splicing lead to the expression of 5 known MTUS1 transcript variants.
Findings
Here, we characterized the 5' untranslated regions of the different transcript variants. We also cloned and functionally tested the alternatively utilized gene promoters that contribute to the production of different MTUS1 transcript variants.
Conclusion
Our results confirmed the early hypothesis that the transcript variants of MTUS1 gene are driven by multiple gene promoters.
Introduction
The MTUS1 gene is located in a region (8p22) that shows frequent loss of heterozygosity (LOH) in several tumor types, including oral cancer [1]. Alternative exon utilization leads to the production of 5 known transcript variants (designated as variant 1 to 5) [2]. It has been suggested that the long form of transcript variants (variant 1, 2, and 3) are driven by a common gene promoter, while variant 4 and 5 are driven by 2 additional promoters [2]. Variant 5 was the first transcript variant to be cloned independently in 2 laboratories, as a gene that is transiently upregulated during initiation of cell differentiation and quiescence [3]. It represents an early component of the growth-inhibiting signaling cascade that interacts with angiotensin II AT2 receptor [4]. Evidence supporting the tumor suppressor function of other MTUS1 variants comes from the study on Xenopus Icis gene, a homolog of MTUS1 variants 1 and 2, which regulates microtubule growth and spindle formation prior to anaphase [5]. Here, we refined the genomic structure of the MTUS1 gene and functionally cloned the alternatively utilized gene promoters that control the production of these MTUS1 transcript variants. This will enhance our understanding on the regulation of this candidate tumor suppressor gene.
Materials and methods
To characterize the 5' untranslated regions (5'-UTR) of the MTUS1 transcript variants, 5'-RACE assays were carried out using human brain reference mRNA (Ambion Inc) and a FirstChoice RLM-RACE kit from Ambion, with primers specific for various transcript variants (Additional file 1). The RACE products were PCR amplified, gel purified and then sequenced. The sequence results have been submitted to the GenBank (accession numbers: FJ458439, FJ458440, FJ458441, FJ472826, and FJ472827 for exon -1a, -1b, -1c, 5, and 8, respectively).
The gene promoter prediction was carried out using MatInspector Professional http://genomatrix.de/cgi-bin/matinspector_prof/mat_fam.pl. The predicted transcription elements of the putative promoters were listed in Additional file 2. To assess the activities of potential gene promoters that control the productions of MTUS1 transcript variants, the following 4 fragments were PCR amplified using specific primers (Additional file 3) and Human Reference Genomic DNA (Promega): 1) a 2286 bp fragment (P1) located at the 5' flanking region of the MTUS1 gene; 2) a 773 bp fragment (P1') located at the 5' flanking region of exon 1; 3) a 529 bp fragment (P2) located at 5' flanking region of exon 5; and 4) a 733 bp fragment (P3) located at 5' flanking region of exon 8. The PCR products were then cloned into the KpnI/XhoI sites of pGL4.10 vector. After verification by DNA sequencing, the constructs were transiently transfected into cells using lipofectamine 2000 (Invitrogen). The pGL4.74 vector (Promega) was co-transfected as internal control for normalization of the transfection efficiency. After 48 hours, transfected cells were harvested with ice-cold phosphate-buffered saline, and dual luciferase assay were performed according to the manufacturer's protocol (Promega) using a Lumat LB 9507 Luminometer (Berthold Technologies).
Results and Discussion
To characterize the 5'-UTRs of MTUS1 transcription variants that are controlled by 3 different gene promoters, 5' RACE assays were performed as described in Materials and Methods section. The 5'RACE assay designed for the long forms of MTUS1 transcription variants (variant 1, 2 and 3) leads to the cloning of the 3 alternatively utilized exons of 91 bp, 169 bp, and 410 bp, respectively (Figure 1B–D). The 3' portion of the exon -1c (281 bp fragment) was previously reported in GenBank (NM_001001924). RT-PCR assays confirm the existence of these non-coding exons (data not shown). The 5'RACE assays designed for transcription variant 4 and 5 confirm the existence of these variants and also refined the 5' untranslated region for variant 5 (Figure 1E and 1F).
Based on sequence conservation and cap-analysis gene expression (CAGE) database, 3 gene promoters were predicted: P1, located at the 5'-flanking region of the gene; P2, located in intron region 5'-flanking exon 5; and P3, located in intron region 5'-flanking exon 8. These gene promoters were supported by sequence conservation (observed in 4, 9, and 11 of 11 orthologous loci analyzed, respectively) and CAGE database (supported by 29, 1 and 13 CAGE tages, respectively). The genomic locations of these putative promoters support the existence of multiple transcript variants of MTUS1 gene (Figure 1A). Interestingly, consensus sequences of relevant transcription elements (TATA-box and multiple CAAT sites) were also observed in a 500 bp fragment located in the intron 5'-flanking the exon 1 (named P1'), which may potentially contribute to the expression of the long transcription variants. We cloned these potential gene promoters and reporter gene assays were performed to evaluate the activities of these promoters using dual luciferase assay in 4 different cell lines, including a human lung fibroblast cell line (WI38), an immortalized normal oral keratinocyte (NOK-16B) and 2 oral tongue SCC cell lines (UM1 and UM2). As illustrated in Table 1, strong promoter activities were observed for P3 in all 4 cell lines tested. Promoter activities were also observed for P1 and P2 in UM1, UM2 and NOK16B, but not in WI38 cells. It is worth noting that transcript variant 4 (controlled by promoter P2) is a brain specific variant [2], which may explains the observed low activity of P2 promoter in our cell lines. No activity was found for negative control (empty pGL4.10 vector). These results confirmed the early hypothesis that the transcript variants of MTUS1 gene are driven by multiple gene promoters. Interestingly, P1', the putative promoter located in the intron region 5'-flanking exon 1 also exhibited strong promoter activity in all 4 cell lines tested, which suggests that the long form of transcript variants (variant 1, 2, and 3) may be regulated by both P1 and P1' promoters. It is possible that these 2 gene promoters may serve a cooperated control circuit in vivo to regulate the expression of this gene. This interesting phenomenon has been observed in a number of other genes, including gene for bradykinin B1 receptor [6], and proto-oncogene MDM2 [7]. Future studies will be needed to fully explore the potential interaction of P1 and P1' promoters.
Table 1.
UM1 | UM2 | NOK16B | WI38 | |
P1 | 2.25 (0.42) | 2.60 (0.20) | 3.03 (0.61) | 0.99 (0.08) |
P1' | 2.63 (0.73) | 5.03 (0.74) | 14.67 (0.21) | 2.72 (0.01) |
P2 | 1.29 (0.02) | 1.34 (0.20) | 1.52 (0.19) | 1.01 (0.29) |
P3 | 4.05 (0.57) | 3.43 (1.33) | 5.48 (2.57) | 6.59 (1.01) |
1 Results presented are averages of at least 2 independent experiments of triplicate measurements. Standard deviations are presented in parentheses.
2 Promoter activities are calculated as the ratios of the averages (Firefly/Renilla) from tested samples and averages (Firefly/Renilla) from negative controls.
In summary, our results refined the genomic structure of the MTUS1 gene and demonstrated the presence of multiple gene promoters. Characterization of this gene will now facilitate studies on the physiological and pathophysiological function and transcriptional regulation of the MTUS1.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
HY and XZ conceived the idea for the project. JY and XL performed the laboratory analyses. JY, HY and XZ drafted the manuscript. All authors read and approved the final manuscript.
Supplementary Material
Acknowledgments
Acknowledgements
This work was supported in part by NIH PHS grants DE014847, DE016569, CA114688, CA139596, and a grant from Prevent Cancer Foundation. We thank Ms. Katherine Long for excellent editorial assistance.
Contributor Information
Jinsheng Yu, Email: jinsheng@uic.edu.
Xiqiang Liu, Email: liuxiqia@uic.edu.
Hui Ye, Email: huiye@uic.edu.
Xiaofeng Zhou, Email: xfzhou@uic.edu.
References
- Ye H, Pungpravat N, Huang BL, Muzio LL, Mariggiò MA, Chen Z, Wong DT, Zhou X. Genomic assessments of the frequent LOH region on 8p22-p21.3 in head and neck squamous cell carcinoma. Cancer Genet Cytogenet. 2007;176:100–106. doi: 10.1016/j.cancergencyto.2007.04.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Di Benedetto M, Bieche I, Deshayes F, Vacher S, Nouet S, Collura V, Seitz I, Louis S, Pineau P, Amsellem-Ouazana D, Couraud PO, Strosberg AD, Stoppa-Lyonnet D, Lidereau R, Nahmias C. Structural organization and expression of human MTUS1, a candidate 8p22 tumor suppressor gene encoding a family of angiotensin II AT2 receptor-interacting proteins, ATIP. Gene. 2006;380:127–136. doi: 10.1016/j.gene.2006.05.021. [DOI] [PubMed] [Google Scholar]
- Seibold S, Rudroff C, Weber M, Galle J, Wanner C, Marx M. Identification of a new tumor suppressor gene located at chromosome 8p21.3-22. Faseb J. 2003;17:1180–1182. doi: 10.1096/fj.02-0934fje. [DOI] [PubMed] [Google Scholar]
- Nouet S, Amzallag N, Li JM, Louis S, Seitz I, Cui TX, Alleaume AM, Di Benedetto M, Boden C, Masson M, Strosberg AD, Horiuchi M, Couraud PO, Nahmias C. Trans-inactivation of receptor tyrosine kinases by novel angiotensin II AT2 receptor-interacting protein, ATIP. J Biol Chem. 2004;279:28989–28997. doi: 10.1074/jbc.M403880200. [DOI] [PubMed] [Google Scholar]
- Ohi R, Coughlin ML, Lane WS, Mitchison TJ. An inner centromere protein that stimulates the microtubule depolymerizing activity of a KinI kinesin. Dev Cell. 2003;5:309–321. doi: 10.1016/S1534-5807(03)00229-6. [DOI] [PubMed] [Google Scholar]
- Yang X, Polgar P. Genomic structure of the human bradykinin B1 receptor gene and preliminary characterization of its regulatory regions. Biochem Biophys Res Commun. 1996;222:718–725. doi: 10.1006/bbrc.1996.0810. [DOI] [PubMed] [Google Scholar]
- Liang H, Lunec J. Characterisation of a novel p53 down-regulated promoter in intron 3 of the human MDM2 oncogene. Gene. 2005;361:112–118. doi: 10.1016/j.gene.2005.07.018. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.